RT Journal Article
SR Electronic
T1 Nivolumab for the Treatment of Advanced Pediatric Malignancies
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 7095
OP 7100
DO 10.21873/anticanres.14738
VO 40
IS 12
A1 MARJAŃSKA, AGATA
A1 DROGOSIEWICZ, MONIKA
A1 DEMBOWSKA-BAGIŃSKA, BOŻENNA
A1 PAWIŃSKA-WĄSIKOWSKA, KATARZYNA
A1 BALWIERZ, WALENTYNA
A1 BOBEFF, KATARZYNA
A1 MŁYNARSKI, WOJCIECH
A1 MIZIA-MALARZ, AGNIESZKA
A1 RACIBORSKA, ANNA
A1 WYSOCKI, MARIUSZ
A1 STYCZYŃSKI, JAN
YR 2020
UL http://ar.iiarjournals.org/content/40/12/7095.abstract
AB Background/Aim: Nivolumab is an immune checkpoint inhibitor with high antitumor activity in selected neoplasms. The aim of the study was to evaluate the efficacy and safety of nivolumab in pediatric patients with various types of highly malignant advanced tumors. Patients and Methods: Ten patients with a median age of 15.1 years were included in the study. The indications for treatment were: malignant skin melanoma (n=5), brain tumor (n=2), malignant melanoma of the brain (n=1), Hodgkin lymphoma (n=1) and soft tissue sarcoma (n=1). Results: Complete disease remission was observed in 4 patients. Overall survival at 24 months from diagnosis for the entire group was 0.36. Two patients receiving combination therapy of nivolumab and ipilimumab did not achieve a remission. Adverse events of immunotherapy were observed in 4/10 patients. Conclusion: Nivolumab is a promising option in pediatric advanced malignancies. Treatment with immunotherapy was relatively well tolerated, and emerging side-effects were manageable.